DHX32 and colorectal carcinoma: In conclusion, this is the first report demonstrating that DHX32 promotes cell proliferation, migration, and invasion, as well as reduces sensitivity to chemotherapy reagents in CRC, via modulating expressions of gene involved in cancer cell growth, migration, and survival.